| Description | Eltoprazine dihydrochloride is a drug that had previously been developed for aggression, has recently been investigated for L-DOPA-induced dyskinesia in animal models of Parkinson′s disease (PD) and in dyskinetic PD patients. |
| In vitro | 在高架十字迷宫实验中，eltoprazine 提高了类似焦虑的行为。另一方面，从约0.3 mg/kg[1]开始，在情境恐惧条件化测试中，它引发了明显的抗焦虑效果。 |
| molecular weight | 293.19 |
| Molecular formula | C12H18Cl2N2O2 |
| CAS | 143485-51-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 10 mg/mL (34.11 mM) |
| References | 1. Gravius A , Dekundy A , Vanaga A , et al. Further pharmacological characterization of eltoprazine: Focus on its anxiolytic, anorexic, and adverse-effect potential[J]. Acta neurobiologiae experimentalis, 2017, 77(1):77-85. 2. Keywood, Charlotte, Widner, et al. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study[J]. Brain: A journal of neurology, 2015. |